Coherus Reports Interim Tagmokitug Data in Esophageal Cancer
The company reported a confirmed objective response rate of 75% in first-line ESCC patients regardless of PD-L1 status, rising to 100% among PD-L1-positive evaluable patients. In second-line ESCC, it observed durable clinical benefit with a dose-response across PD-L1 status and in PD-1-refractory patients.